EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Prognostic significance of the CRP–albumin–lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis

Wen Xu, Daqin Zhan, Ruolan Wang, Shu Jin, Xiao-Bo Liu

PeerJ · 22.05.2026 · 14 · e21277

DOI: 10.7717/peerj.21277 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PeerJ, online erschienen am 22.05.2026. Verfasst von Wen Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, C-Reactive Protein, Serum Albumin, Lymphocytes. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Shiyan City Science and Technology Bureau Guiding Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Esophageal cancer (EC) is associated with marked regional disparities, poor 5-year survival (15%–25%), and limited progress in therapeutic outcomes. The tumor, node, and metastasis (TNM) staging system has reduced accuracy for long-term survival prediction, particularly after neoadjuvant therapy. The C-reactive protein–albumin–lymphocyte (CALLY) index—integrating inflammation (C-reactive protein), nutrition (albumin), and immunity (lymphocytes)—emerges as a novel prognostic biomarker. This study aims to evaluate its association with survival outcomes in patients with EC.

Methods

Following the PRISMA guidelines and PROSPERO registration (CRD420251125031), two researchers independently screened and extracted data from all relevant original articles published from database inception to July 2025. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) score. Meta-analysis was performed using RevMan 5.3 software, and the risk of bias was assessed using risk of bias plots and funnel plots.

Results

Seven studies involving 2,243 patients were included in this meta-analysis. Pooled multivariate analyses of the included studies demonstrated that the CALLY index was independently associated with 5-year overall survival (OS) and recurrence-free survival (RFS), with a high CALLY index consistently predicting favorable outcomes. Moreover, patients with EC in the high CALLY index group had better 5-year OS and RFS than those in the low CALLY index group.

Conclusion

The pretreatment CALLY index is a robust prognostic biomarker that is independently associated with improved OS and RFS in patients with EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsC-Reactive ProteinSerum AlbuminLymphocytesHumansPrognosisBiomarkers, TumorLymphocyte Count

Stichwörter der Autor:innen

CRP–albumin–lymphocyte indexEsophageal cancerMeta-analysis

Substanzen

C-Reactive ProteinBiomarkers, TumorSerum Albumin

Autor:innen und Institutionen

  • Department of Gastroenterology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
  • Department of Pediatrics, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.

Förderung

  • The Shiyan City Science and Technology Bureau Guiding Research Project

Zitieren

APA

Xu, W., Zhan, D., Wang, R., Jin, S., & Liu, X. B. (2026). Prognostic significance of the CRP–albumin–lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis. PeerJ, 14, e21277. https://doi.org/10.7717/peerj.21277

Vancouver

Xu W, Zhan D, Wang R, Jin S, Liu XB. Prognostic significance of the CRP–albumin–lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis. PeerJ. 2026;14:e21277. doi:10.7717/peerj.21277

BibTeX
@article{Xu2026,
  author = {Xu, Wen and Zhan, Daqin and Wang, Ruolan and Jin, Shu and Liu, Xiao-Bo},
  title = {Prognostic significance of the CRP–albumin–lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21277},
  doi = {10.7717/peerj.21277}
}
Kostenlos starten →